Torrent Pharmaceuticals Limited
TORNTPHARM
Rank in Stocks
#1199
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Share Price
$50.31
Last synced: 2026-10-19
Market Cap
$19.14B
Change (1 day)
-0.14%
Change (1 year)
23.83%
Country
IN
Trade Torrent Pharmaceuticals Limited (TORNTPHARM)
Category
Healthcare
P/B ratio for Torrent Pharmaceuticals Limited (TORNTPHARM)
P/B ratio as of October 2026 TTM: 8.89
According to Torrent Pharmaceuticals Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 8.89. At the end of 2024 the company had a P/B ratio of 13.21.
P/B ratio history for Torrent Pharmaceuticals Limited from 2005 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 8.89 | -37.38% |
| 2025 | 14.19 | 7.48% |
| 2024 | 13.21 | 57.34% |
| 2023 | 8.39 | 5.76% |
| 2022 | 7.94 | 7.57% |
| 2021 | 7.38 | 6.65% |
| 2020 | 6.92 | 1.65% |
| 2019 | 6.81 | 46.79% |
| 2018 | 4.64 | -23.24% |
| 2017 | 6.04 | -9.75% |
| 2016 | 6.69 | -14.99% |
| 2015 | 7.87 | 68.81% |
| 2014 | 4.66 | 14.99% |
| 2013 | 4.06 | -9.26% |
| 2012 | 4.47 | -6.96% |
| 2011 | 4.80 | -13.51% |
| 2010 | 5.55 | 218.83% |
| 2009 | 1.74 | -25.49% |
| 2008 | 2.34 | -42.11% |
| 2007 | 4.04 | -23.55% |
| 2006 | 5.28 | 77.99% |
| 2005 | 2.97 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -43.26% |
IN
|
